<DOC>
	<DOCNO>NCT00568737</DOCNO>
	<brief_summary>Adult Patients Severe Sepsis</brief_summary>
	<brief_title>The Study Drotrecogin Alfa ( Activated ) Adult Patients With Severe Sepsis Low Risk Death</brief_title>
	<detailed_description>Compared placebo , drotrecogin alfa ( activate ) reduce 28-day all-cause mortality adult patient severe sepsis low risk death ( example , Acute Physiology Chronic Health Evaluation II ( APACHE II ) score &lt; 25 single organ dysfunction ) .</detailed_description>
	<mesh_term>Sepsis</mesh_term>
	<mesh_term>Toxemia</mesh_term>
	<mesh_term>Drotrecogin alfa activate</mesh_term>
	<mesh_term>Protein C</mesh_term>
	<criteria>Adult patient recent onset severe sepsis presence suspect proven infection , least one induced organ dysfunction . Are indicated treatment drotrecogin alfa ( activate ) applicable label investigative site country . Are contraindicated treatment drotrecogin alfa ( activate ) applicable label investigative site country . Platelet count less 30,000/mm3 .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>December 2007</verification_date>
	<keyword>Severe Sepsis</keyword>
</DOC>